US SEC Trading Suspension Halt Orders — August 25, 2026

25-08-2026

Datavault AI Inc. (DVLT) received a Nasdaq extension notice on August 25, 2026, granting an additional 180 calendar days, until February 22, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company failed to meet the initial compliance deadline of August 24, 2026, and its stock continues to trade on the Nasdaq Capital Market under the symbol 'DVLT' while it considers options including a potential reverse stock split. However, there is no assurance that compliance will be achieved, and failure to do so could result in delisting.

• · The initial non-compliance letter was received on February 24, 2026, and disclosed in an 8-K filed February 27, 2026.
• · The extension was granted because the company met the continued listing requirement for market value of publicly held shares and all other applicable initial listing requirements except the minimum bid price.
• · The company provided written notice of its intention to cure the deficiency, including by effecting a reverse stock split if necessary.
• · If compliance is not regained by February 22, 2027, Nasdaq will issue a delisting notice, and the company may appeal to a hearings panel, though success is not assured.

25-08-2026

Barinthus Biotherapeutics plc notified Nasdaq of its intent to withdraw its American Depositary Shares (ADSs) from listing, effective with a scheme of arrangement under the UK Companies Act expected to close on September 3, 2026. The delisting is part of a merger with Clywedog Therapeutics, after which the combined entity will be renamed Clywedog Therapeutics Holdings, Inc. and list on Nasdaq under the ticker 'CLYD'. The Scheme Exchange Ratio was set at 0.111 to satisfy Nasdaq's minimum price requirement for the new listing.

• · Trading of ADSs on Nasdaq is expected to halt prior to the opening of trading on September 3, 2026.
• · The company will file a Form 15 with the SEC to deregister the ADSs and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.
• · The court hearing for the scheme is scheduled for September 1, 2026 at the Royal Courts of Justice, London.
• · The Merger Exchange Ratio will be determined immediately prior to closing based on the Scheme Exchange Ratio and adjustments in the Merger Agreement to maintain the agreed ownership split.

25-08-2026

La Rosa Holdings Corp. reported mixed first-half 2026 results: gross profit grew 9.9% to $3.7M and operating loss narrowed 41.6% to $4.2M, but total revenue declined 18.0% to $28.6M, partly due to the sale of a non-core subsidiary. Net loss improved 9.4% to $15.6M, though the company faces a significant going-concern risk and Nasdaq listing compliance issues, as highlighted in the forward-looking statements.

• · Total liabilities ($28.8M) exceeded total assets ($21.0M) as of June 30, 2026, resulting in a stockholders' deficit of $7.8M.
• · Cash and cash equivalents declined 26.0% from $3.1M at Dec 31, 2025 to $2.3M at June 30, 2026.
• · The company reported $10.3M in restricted digital assets on the balance sheet as of June 30, 2026, compared to none in the prior year.
• · Common shares outstanding surged from 20,963 at Dec 31, 2025 to 2,025,470 at June 30, 2026, a 96-fold increase.
• · The company's net loss per share (basic) improved from $(3,200.14) in H1 2025 to $(22.73) in H1 2026, reflecting massive share dilution.
• · Q2 2026 net loss of $2.2M contrasts sharply with Q2 2025 net income of $78.5M, which included an $82.3M gain on warrant settlement.
• · The company sold its 51% interest in LR Kissimmee in February 2026, which represented ~10% of its agent base but was not cash-flow positive.
• · Forward-looking statements explicitly note risks including ability to continue as a going concern and maintain Nasdaq listing compliance.

25-08-2026

Fathom Holdings Inc. received a Nasdaq notice on August 21, 2026, for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has a 180-day compliance period until February 17, 2027, to regain compliance, and its stock continues to trade on the Nasdaq Capital Market under "FTHM" with no immediate delisting effect. The company is evaluating options but cannot assure compliance.

• · The company may be eligible for an additional 180-day compliance period if it meets other continued listing standards and provides notice of intent to cure, including a potential reverse stock split.
• · If compliance is not regained, Nasdaq will provide a delisting notice, and the company may appeal to a Nasdaq hearings panel.

25-08-2026

Maison Solutions Inc. (MSS) received a Nasdaq deficiency notice on August 20, 2026, for failing to timely file its Annual Report (Form 10-K) for the fiscal year ended April 30, 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days (until October 19, 2026) to submit a compliance plan; if accepted, Nasdaq may grant an exception until February 9, 2027. The stock continues trading on Nasdaq under symbol 'MSS' with no immediate delisting effect, but the company faces a material risk of delisting if it fails to regain compliance.

• · The company's Class A common stock continues to trade on The Nasdaq Capital Market under symbol 'MSS' with no immediate effect on listing.
• · If Nasdaq does not accept the compliance plan, the company may appeal to a Nasdaq Hearings Panel.
• · The company operates grocery retail stores in Southern California and Arizona under the HK Good Fortune and Lee Lee International brands.

25-08-2026

BioRestorative Therapies, Inc. (BRTX) received a Nasdaq delinquency notice on August 21, 2026, for failing to timely file its Form 10-Q for the quarter ended June 30, 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has until October 20, 2026, to submit a compliance plan, with a potential extension to February 16, 2027, but faces delisting risk if it fails to regain compliance. The stock continues to trade on Nasdaq, but the company's inability to file timely financial reports signals ongoing operational and financial reporting challenges.

• · The company has until October 20, 2026, to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).
• · If Nasdaq accepts the plan, an exception of up to 180 calendar days from the Form 10-Q's due date, or until February 16, 2027, may be granted.
• · If the compliance plan is not accepted, the company may appeal to a Nasdaq Hearings Panel.
• · The company's common stock continues to trade on The Nasdaq Capital Market under the symbol 'BRTX'.

25-08-2026

Aimei Health Technology Co., Ltd. received two Nasdaq deficiency notices on August 21, 2026, for failing to meet the minimum Market Value of Listed Securities ($50 million) and minimum Market Value of Publicly Held Shares ($15 million) requirements for continued listing on the Nasdaq Global Market. The company has a 180-day compliance period, until February 17, 2027, to regain compliance, but there is no assurance it will succeed, and its securities could be delisted.

• · The company's ordinary shares continue to trade on Nasdaq Global Market under symbol 'AFJK' with no immediate effect on listing.
• · If compliance is not regained, the company may consider transferring to the Nasdaq Capital Market if it meets that market's listing requirements.
• · The company intends to monitor its MVLS and MVPHS and consider available options, but there is no assurance of success.